Could less chemo be better for older breast cancer patients?
NCT ID NCT06042569
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether giving a lower dose of two chemotherapy drugs (docetaxel and cyclophosphamide) can work well and cause fewer side effects in women aged 65 and older with early-stage HER2-negative breast cancer. The goal is to help these women complete their treatment with less harm to their physical and emotional well-being. About 174 participants will be enrolled to compare the lower dose to the standard dose.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANATOMIC STAGE I BREAST CANCER AJCC V8 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
City of Hope Medical Center
RECRUITINGDuarte, California, 91010, United States
-
Dana-Farber Cancer Institute
RECRUITINGBoston, Massachusetts, 02215, United States
-
University of Rochester
RECRUITINGRochester, New York, 14642, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Fasting during chemo: a new way to boost treatment?
- Gut bacteria may fortify bones in breast cancer therapy
- Can a smart drug cross the Blood-Brain barrier to attack breast cancer metastases?
- Digital therapy aims to tame the fear that haunts cancer survivors
- A remote diet and exercise program aims to help rural cancer survivors shed pounds and lower recurrence risk
- Engineered immune cells join chemo and antibody to attack Hard-to-Treat breast cancer